<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03272165</url>
  </required_header>
  <id_info>
    <org_study_id>D6340C00001</org_study_id>
    <nct_id>NCT03272165</nct_id>
  </id_info>
  <brief_title>Single Ascending Dose Study of MEDI1341 in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MMS Holdings, Inc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catalent</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of single ascending intravenous doses of MEDI1341 or placebo in up to 48&#xD;
      healthy volunteers, aged 18 to 65 years.&#xD;
&#xD;
      The study will include up to 6 planned cohorts; each cohort will comprise 8 subjects.&#xD;
&#xD;
      Each subject will receive a single 60 minute intravenous infusion of MEDI1341 or placebo and&#xD;
      will undergo scheduled assessments over a period of 13 weeks.&#xD;
&#xD;
      The main aim of the study is to assess the safety and tolerability of single doses of&#xD;
      MEDI1341 in Healthy Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study of single ascending intravenous&#xD;
      doses of MEDI1341 in male and nonfertile female healthy volunteers, aged 18 to 65 years.&#xD;
&#xD;
      The study will include up to 6 planned cohorts; each cohort will comprise 8 subjects. Within&#xD;
      each cohort, 6 subjects will be randomized to receive MEDI1341 and 2 will be randomized to&#xD;
      receive placebo. A Safety Review Committee will review data from each cohort before&#xD;
      progression to the next higher dose cohort occurs.&#xD;
&#xD;
      On Day 1, each randomized subject will receive a single 60 minute intravenous infusion of&#xD;
      MEDI1341 or placebo and will undergo scheduled safety, pharmacokinetic, pharmacodynamic, and&#xD;
      immunogenicity assessments. Additional study assessments will occur on Days 2, 4, 8, 15, 22,&#xD;
      29, 43, 57, and 92.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects are randomised to one of two groups within a cohort of 8 subjects (N=6 MEDI1341; N=2 placebo)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>13 weeks</time_frame>
    <description>- Incidence, nature, severity and seriousness</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital Signs</measure>
    <time_frame>13 weeks</time_frame>
    <description>- Blood pressure and pulse rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral Body Temperature</measure>
    <time_frame>13 weeks</time_frame>
    <description>- in Celsius</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body weight</measure>
    <time_frame>13 weeks</time_frame>
    <description>- in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Height</measure>
    <time_frame>13 weeks</time_frame>
    <description>- in meters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>13 weeks</time_frame>
    <description>- Weight and height will be combined to report BMI in kg/m2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Laboratory tests</measure>
    <time_frame>13 weeks</time_frame>
    <description>- Clinical chemistry, hematology, coagulation, urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiograms</measure>
    <time_frame>13 weeks</time_frame>
    <description>- rhythm, heart rate, conduction, P-R interval, QRS complex, R-R interval, Q-T interval, and QTcF (Q-T interval corrected by Fridericia's formula)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ophthalmic assessments</measure>
    <time_frame>13 weeks</time_frame>
    <description>a standardized ophthalmic patient-reported outcome questionnaire&#xD;
visual acuity&#xD;
intraocular pressure&#xD;
corneal thickness&#xD;
slit-lamp examination&#xD;
fundoscopy&#xD;
optical coherence tomography&#xD;
visual field assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration of Medi1341</measure>
    <time_frame>13 weeks</time_frame>
    <description>- Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration of Medi1341</measure>
    <time_frame>13 weeks</time_frame>
    <description>- tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration - time curve of Medi1341</measure>
    <time_frame>13 weeks</time_frame>
    <description>- AUC from zero to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of Medi1341 from zero to infinity</measure>
    <time_frame>13 weeks</time_frame>
    <description>- AUC0-∞</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life of Medi1341</measure>
    <time_frame>13 weeks</time_frame>
    <description>- t1/2λz</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of Medi1341</measure>
    <time_frame>13 weeks</time_frame>
    <description>- CL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution of Medi1341 at steady state</measure>
    <time_frame>13 weeks</time_frame>
    <description>- Vss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean residence time of Medi1341</measure>
    <time_frame>13 weeks</time_frame>
    <description>- MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total alpha-synuclein concentrations</measure>
    <time_frame>13 weeks</time_frame>
    <description>- in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free alpha-synuclein concentrations</measure>
    <time_frame>29 days</time_frame>
    <description>- in Cerebrospinal Fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Drug Antibodies to MEDI1341</measure>
    <time_frame>13 weeks</time_frame>
    <description>- in serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>MEDI1341</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI1341</intervention_name>
    <description>Intravenous infusion over 60 minutes</description>
    <arm_group_label>MEDI1341</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion over 60 minutes</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must be healthy, with no clinically significant abnormality identified on the&#xD;
             medical or laboratory evaluation at screening&#xD;
&#xD;
          -  Subjects must weigh ≥50 kg and must have a body mass index between 18 and 32 kg/m2,&#xD;
             inclusive&#xD;
&#xD;
          -  Subjects must have a 12-lead ECG recorded at screening that is normal for the&#xD;
             appropriate age group and shows no abnormalities that will compromise safety in this&#xD;
             study&#xD;
&#xD;
          -  Subjects must have no clinically significant findings on the clinical neurological&#xD;
             examinations at screening and at baseline or on the ophthalmic examination at&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nicotine use within 6 months before screening&#xD;
&#xD;
          -  Considered to be at a high risk of developing a stroke&#xD;
&#xD;
          -  Significant medical history of dizziness, blackouts, fainting, or vaso-vagal attacks&#xD;
&#xD;
          -  History of any significant ophthalmic disorder, including congenital, genetic or&#xD;
             acquired conditions affecting the retina or choroid&#xD;
&#xD;
          -  History of severe allergy or history of hypersensitivity to immunizations or&#xD;
             immunoglobulins&#xD;
&#xD;
          -  History of any significant psychiatric disorder&#xD;
&#xD;
          -  History of alcohol abuse&#xD;
&#xD;
          -  History of cancer within 5 years of screening&#xD;
&#xD;
          -  History of drug abuse&#xD;
&#xD;
          -  Any contraindication to Lumbar Puncture&#xD;
&#xD;
          -  Any clinically significant abnormality in ECG rhythm, conduction or morphology&#xD;
&#xD;
          -  Positive serologic findings at screening for human immunodeficiency virus (HIV)&#xD;
             antibodies, hepatitis B surface antigen, or hepatitis C virus antibodies&#xD;
&#xD;
          -  Use of prescription or non-prescription drugs&#xD;
&#xD;
          -  For female subjects, a positive serum or urine pregnancy test result at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeanelle Kam, MD, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Dallas CRU, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John E Blanchard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Madison CRU, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Immunogenicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymised individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved, AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsor tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

